Branched-chain amino acids (BCAAs) composed of valine, leucine, and isoleucine are essential amino acids and account for about 40% of dietary essential amino acids in body protein and about 15% of total amino acids in muscle proteins (1). BCAAs play a role in delayed onset of muscle soreness and fatigue, and suppression of fatigue in the central nervous system (2, 3). BCAAs have been also used for the prevention of hepatic encephalopathy in patients with liver cirrhosis (4, 5). Recently, sport enthusiasts have created an increased demand for dietary supplements with BCAAs and have increased their consumption of BCAAs-enriched soft drinks.
Branched-chain amino acids (BCAAs) composed of valine, leucine, and isoleucine are essential amino acids and account for about 40% of dietary essential amino acids in body protein and about 15% of total amino acids in muscle proteins (1) . BCAAs play a role in delayed onset of muscle soreness and fatigue, and suppression of fatigue in the central nervous system (2, 3) . BCAAs have been also used for the prevention of hepatic encephalopathy in patients with liver cirrhosis (4, 5) . Recently, sport enthusiasts have created an increased demand for dietary supplements with BCAAs and have increased their consumption of BCAAs-enriched soft drinks.
The first step in the catabolism of BCAAs involves branched-chain aminotransferase (BCAT; EC 2.6.1.42), a common enzyme. This enzyme requires vitamin B 6 , which functions as a cofactor in many enzyme reactions of amino acid metabolism (6, 7) . However, little information is available on the relationship between supplementation with BCAAs and the recommended daily allowance of vitamin B6. In addition, it is known that a high-protein diet (e.g., 70% casein diet) under vitamin B6 deficiency has a negative impact on several biochemical parameters and leads to fatty liver in rats (8) (9) (10) .
Our previous study showed that providing supplemented BCAAs under vitamin B6 deficiency and a 20% casein diet caused an accumulation of triacylglycerol in the liver, and individual differences in biological responses were observed (11) . It is possible that a disorder of amino acid metabolism in the presence of vitamin B6 deficiency might influence the assembly of lipids and apolipoproteins and/or the secretion of lipoproteins. Among the serum lipoproteins, very low-density lipoprotein (VLDL) is present during endogenous lipogenesis in the liver and its major apolipoproteins are apolipoprotein (apo) B, apo C, and apo E (12) . It is interesting to compare serum apo B and apo E levels, and hepatic apoE levels to evaluate lipid deposition, because apo B and apo E are key determinants responsible for cellular recognition and internalization of chylomicron remnants, VLDL, and high-density lipoprotein (HDL) (13, 14) . In this study, we investigated the possible mechanism of lipid deposition in the liver of rats fed with the supplementation of BCAA under vitamin B 6 deficiency and suggested the presence of impaired secretion of VLDL into the bloodstream from the liver.
Materials and Methods
Diets and animals. Four diets composed of purified 20% vitamin-free casein diet with (1) or without (2) vitamin B6 (7.0 mg of pyridoxine HCl/kg of diet) and with (1) Isolation of lipoproteins and purification of apo E. Isolation and purification of VLDL (d,1.006 g/mL) using preparative ultracentrifugation from pooled serum of male Wistar rats and delipidation of VLDL were performed as described previously (16) (17) (18) . Delipidated VLDL (40-45 mg) was solubilized in 6 m guanidine HCl and 0.05 m Tris-HCl (pH 8.4) containing 0.1% NaN3 and was applied on Sepharose CL-6B. Apo E fractions corresponding to a molecular weight of 34,000-36,000 were exhaustively dialyzed against distilled water, lyophilized, and used for calibration of apo E.
Enzyme-linked immunoassay (ELISA) of serum and hepatic apolipoproteins. Serum apo B levels were determined using an ELISA kit (Uscn, Life Science, Inc., Wuhan, China). Serum and hepatic apo E levels were determined as follows. Polyvinylchloride microtiter plates were coated with the diluted rat serum in carbonate buffer (pH 9.6) containing 0.02% NaN3 at 4˚C overnight. For the preparation of liver samples, liver was homogenized with PBS buffer (pH 7.4) and an aliquot of solution was freeze-dried. Delipidation of freeze-dried liver was performed as described previously (18) . Delipidated liver was solubilized with carbonate buffer (pH 9.6) containing 0.02% NaN3, and the supernatant was used for coating plates. Apo E levels were measured by ELISA using two antibodies against goat anti-rat apo E as a first antibody (Santa Cruz Biotechnology, Inc., CA, USA) and horseradish peroxidase conjugated rabbit anti-goat IgG as a second antibody (R & G Systems, MN, USA). The procedure was previously described in detail except for 230 mm 3,3′,5,5′-tetramethylbenzidine and 0.02% H2O2 in 200 mm citrate buffer (pH 5.3) (19) . The developed color was determined at 450 nm for apo B and apo E with a microplate reader (model 680, Bio-Rad Laboratories, Richmond, CA, USA).
Lipoprotein analysis. Serum lipoproteins were analyzed by an on-line dual detection high performance lipid chromatography (HPLC) system (Skylight Biotech, Inc., Akita, Japan) according to the procedure described by Usui et al. (20, 21) .
Lipid analysis and other measurements. Hepatic lipids were extracted and purified according to the method of Folch et al. (22) . Hepatic triacylglycerol, phospholipid, and cholesterol levels were determined colorimetrically as previously described (23) . Serum triacylglycerol, phospholipids, and HDL cholesterol were determined using an enzymatic assay kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Serum total cholesterol, albumin, and aspartate aminotransferase levels were determined by Fuji DRI-CHEM 3030 (Fuji Film Medical Co., Inc., Tokyo, Japan). Protein concentrations of the liver protein and purified apo E protein were determined using with bovine serum albumin as the standard (24) .
Statistical analysis was performed using the TukeyKramer multiple range test. All statistical tests were done with SPSS 14.0J for Windows (SPSS Inc., IL, USA). A p value ,0.05 was considered statistically significant.
Results and Discussion
Growth parameters and tissue weight of rats fed different diets are shown in Table 2 . After 21 d, fat infiltration of the liver was observed via gross examination, liver weight per body weight, and hepatic triacylglycerol 5 levels in six of 12 rats fed the B6(2)BCAA(1) diet. Final body weight and food intake were significantly lower in the two B6(2) groups compared with the two B6(1) groups. The relative liver weight in the B6(2)BCAA(1) group was significantly increased compared with the other three groups. The relative kidney weight of the two B6(2) groups was significantly increased compared with that of the two B6(1) groups, and the relative epididymal adipose tissue weight of the B6(2)BCAA(1) group was significantly lower than that of the two B6 (1) groups. In addition, the relative thymus weight of the two B6(2) groups was significantly decreased compared with that of the two B6(1) groups. Results in growth parameters and tissue weight in B6 deficiency were similar to a previous study (11) .
Serum and hepatic lipids levels and growth indices are shown in Table 3 . Aspartate aminotransferase activity of the two B6(2) groups was significantly decreased to one third of the two B6(1) groups. Serum triacylglycerol, phospholipids, cholesterol, and HDL-cholesterol levels were not remarkably different among the four groups. The preparation of experimental diets and its abbreviation are described in Table 1 .
Values are means6SD of six rats except for 12 rats of the B6 (2)BCAA (1) group. Different superscript letters indicate significant differences at p,0.05. Table 3 . Serum and hepatic lipid concentrations and growth indices of rats fed experimental diets.
B6 (1)BCAA (2) B6 (1)BCAA (1) B6 (2)BCAA (2) B6 (2) B6 (1)BCAA (2) B6 (1)BCAA (1) B6 (2)BCAA (2) B6 (2) Hepatic triacylglycerol and phospholipids levels were not significantly different among groups. However, hepatic triacylglycerol levels of the B6(2)BCAA(1) group were two to three-fold higher than those in the other three groups, although differences were not significant. The hepatic triacylglycerol levels of the 12 rats in the B6(2)BCAA(1) group ranged from 11.4 to 145 mg per g liver, which may explain the differences compared with the other groups. Hepatic cholesterol levels in the B6(2)BCAA(1) group were significantly increased compared with the B6(1)BCAA(1) group.
These results that about half of the rats fed the B6(2)BCAA(1) diet showed lipid deposition in the liver were not experimental errors. Similar results were also observed in our previous report (11) and another three experimental results (unpublished data).
Serum and hepatic apolipoprotein levels determined by ELISA are shown in Table 4 . Serum apo B and apo E levels in the B6(2)BCAA(1) group were the lowest among all groups, and apo B levels in the B6(2) BCAA(1) group were significantly decreased compared with the other three groups. In addition, serum apo E levels in the B6(2)BCAA(1) group were also significantly decreased compared with that of the B6 (1) BCAA (2) group. On the other hand, hepatic apo E levels were not significantly different among the four groups, although apo E levels in the B6(2)BCAA(1) group were the highest among the groups. In this study, hepatic apo B levels could not be determined because of insolubility of the characteristic of this apoprotein with the assay system (25) . It is interesting to note that both hepatic triacylglycerol and apo E levels in the B6 (2)BCAA (1) group tended to increase, but serum triacylglycerol, apo B, and apo E levels tended to decrease. It is known that endogenously synthesized triacylglycerol in the liver is secreted as VLDL into the blood after being assembled with apolipoproteins such as apo B, apo C, and apo E as well as lipids (26) . Therefore, it can be inferred from our data that the secretion of synthesized lipoproteins from the liver to the bloodstream might be impaired. As described in this study, hepatic triacylglycerol levels with the B6(2)BCAA(1) group of 12 rats ranged from 11.4 to 145 mg per g liver. We then subdivided the B6(2)BCAA(1) group into two groups on the basis of hepatic triacylglycerol levels: 11.4 to 17.1 mg per g liver was considered a normal liver, and 37.7 to 145 mg per g liver was considered to represent lipid deposits. Then, the profile of serum lipoproteins was analyzed and compared among the three other groups and the two B6(2) BCAA(1) subgroups.
HPLC analyses of serum lipoprotein profiles are shown in Fig. 1 . The retention time of VLDL, LDL, and HDL were 20.5 min, 22.6 min, and 25.5 min, respectively. The pooled serum of lipid-deposited livers in the B6(2) BCAA(1) group showed decreased triacylglycerol levels in VLDL compared with the B6(2)BCAA(1) group with no fatty liver deposits and with the other three groups. However, no differences in triacylglycerol or cholesterol levels of LDL or HDL were observed among these five groups. These lipoprotein profiles also support the mechanism by which the B6(2)BCAA(1) diet induced the lipid deposition in the liver due to the impaired secretion of VLDL from the liver into the bloodstream.
In this study, it is not clear why only half the rats fed Fig. 1 . HPLC profiles of serum lipid concentrations of lipoproteins of rats fed four different experimental diets. Pooled serum from each group was subjected to HPLC analysis, and triacylglycerol (solid lines) and cholesterol levels (dashed lines) in effluents were monitored. The retention times of very low-density lipoprotein, low-density lipoprotein, and highdensity lipoprotein were 20.5 min, 22.6 min, and 25.5 min, respectively. The composition of the experimental diets is described in Table 1 . The B6(2)BCAA(1) group was subdivided into two groups: normal liver or liver with lipid deposits, based on hepatic triacylglycerol levels. 
